Click here to read the news release.
About Cliff GorskiThis author has not yet filled in any details.
So far Cliff Gorski has created 45 blog entries.
UMDF joins NORD statement Statement in Opposition to the Senate’s Proposed Weakening of the Orphan Drug Tax CreditCliff Gorski 2017-11-15T15:11:17+00:00
UMDF signed onto this statement, see it here.
Stealth BioTherapeutics Initiates Phase 3 Study of Elamipretide in Patients with Primary Mitochondrial MyopathyCliff Gorski 2017-11-06T14:10:19+00:00
Click here for details
Click here to see the report. You can see the MMS Consensus Report here
KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers.Cliff Gorski 2017-10-23T15:17:22+00:00
See more here.
Mitochondria are moving into the mainstream scientific limelight, thanks in large part to Douglas Wallace, PhD, the “world’s biggest mitochondriac” who is galvanizing research on the Penn and CHOP campuses into the role of cellular energy in disease.”Cliff Gorski 2017-10-19T10:13:58+00:00
Click here to read article.
Click here to see complete story.
Dr Mark Korson Joins VMP Genetics Expanding Metabolic Medicine Services to Physicians, Hospitals, and Institutions WorldwideCliff Gorski 2017-10-10T14:36:28+00:00
VMP Genetics and Dr. Fran Kendall, pioneers in rare genetics and telemedicine, are pleased to announce that Dr. Mark Korson has joined VMP as the Director of Physician Support and Educational Services divisions. Expanding these two divisions extends our reach beyond current direct patient care and remote second opinion services into medical consultation to [...]
Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial MyopathyCliff Gorski 2017-10-02T11:02:06+00:00
BOSTON, October 2, 2017 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to Stealth's investigational drug candidate, elamipretide, for the treatment of patients with primary mitochondrial myopathy (PMM). [...]